{"downloaded": true, "htmlmade": false, "full": {"id": "30287523", "source": "MED", "pmid": "30287523", "pmcid": "PMC6284216", "fullTextIdList": {"fullTextId": "PMC6284216"}, "doi": "10.1182/blood-2018-05-850461", "title": "The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.", "authorString": "Flinn IW, Hillmen P, Montillo M, Nagy Z, Ill\u00e9s \u00c1, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.", "authorList": {"author": [{"fullName": "Flinn IW", "firstName": "Ian W", "lastName": "Flinn", "initials": "IW", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Sarah Cannon Research Institute, Nashville, TN."}, {"affiliation": "Tennessee Oncology, Nashville, TN."}]}}, {"fullName": "Hillmen P", "firstName": "Peter", "lastName": "Hillmen", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "St. James's Institute of Oncology, The Leeds Teaching Hospitals, Leeds, United Kingdom."}}}, {"fullName": "Montillo M", "firstName": "Marco", "lastName": "Montillo", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology and Oncology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy."}}}, {"fullName": "Nagy Z", "firstName": "Zsolt", "lastName": "Nagy", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "First Department of Internal Medicine, Semmelweis University, Budapest, Hungary."}}}, {"fullName": "Ill\u00e9s \u00c1", "firstName": "\u00c1rp\u00e1d", "lastName": "Ill\u00e9s", "initials": "\u00c1", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary."}}}, {"fullName": "Etienne G", "firstName": "Gabriel", "lastName": "Etienne", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Institut Bergonie, Bordeaux, France."}}}, {"fullName": "Delgado J", "firstName": "Julio", "lastName": "Delgado", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0002-5157-4376"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hospital Clinic, Barcelona, Spain."}}}, {"fullName": "Kuss BJ", "firstName": "Bryone J", "lastName": "Kuss", "initials": "BJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Flinders Medical Centre-Flinders University, Bedford Park, SA, Australia."}}}, {"fullName": "Tam CS", "firstName": "Constantine S", "lastName": "Tam", "initials": "CS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Peter MacCallum Cancer Centre, St. Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia."}}}, {"fullName": "Gasztonyi Z", "firstName": "Zolt\u00e1n", "lastName": "Gasztonyi", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine and Hematology, Petz Alad\u00e1r County Hospital, Gy\u0151r, Hungary."}}}, {"fullName": "Offner F", "firstName": "Fritz", "lastName": "Offner", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology, University Hospital Ghent, Gent, Belgium."}}}, {"fullName": "Lunin S", "firstName": "Scott", "lastName": "Lunin", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Florida Cancer Specialists, Venice, FL."}}}, {"fullName": "Bosch F", "firstName": "Francesco", "lastName": "Bosch", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain."}}}, {"fullName": "Davids MS", "firstName": "Matthew S", "lastName": "Davids", "initials": "MS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA."}}}, {"fullName": "Lamanna N", "firstName": "Nicole", "lastName": "Lamanna", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "New York Presbyterian, Columbia University Medical Center, New York, NY."}}}, {"fullName": "Jaeger U", "firstName": "Ulrich", "lastName": "Jaeger", "initials": "U", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria."}}}, {"fullName": "Ghia P", "firstName": "Paolo", "lastName": "Ghia", "initials": "P", "authorId": {"@type": "ORCID", "#text": "0000-0003-3750-7342"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Universita' Vita-Salute San Raffaele and San Raffaele Scientific Institute, Milan, Italy."}}}, {"fullName": "Cymbalista F", "firstName": "Florence", "lastName": "Cymbalista", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Laboratoire d'h\u00e9matologie, H\u00f4pital Avicenne, Paris, France."}}}, {"fullName": "Portell CA", "firstName": "Craig A", "lastName": "Portell", "initials": "CA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, University of Virginia, Charlottesville, VA."}}}, {"fullName": "Skarbnik AP", "firstName": "Alan P", "lastName": "Skarbnik", "initials": "AP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ."}}}, {"fullName": "Cashen AF", "firstName": "Amanda F", "lastName": "Cashen", "initials": "AF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Siteman Comprehensive Cancer Center, Washington University, St. Louis, MO."}}}, {"fullName": "Weaver DT", "firstName": "David T", "lastName": "Weaver", "initials": "DT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Verastem Oncology, Needham, MA."}}}, {"fullName": "Kelly VM", "firstName": "Virginia M", "lastName": "Kelly", "initials": "VM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Verastem Oncology, Needham, MA."}}}, {"fullName": "Turnbull B", "firstName": "Barry", "lastName": "Turnbull", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Verastem Oncology, Needham, MA."}}}, {"fullName": "Stilgenbauer S", "firstName": "Stephan", "lastName": "Stilgenbauer", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany; and."}, {"affiliation": "Klinik f\u00fcr Innere Medizin I, Universit\u00e4tsklinikum des Saarlandes, Homburg, Germany."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-5157-4376"}, {"@type": "ORCID", "#text": "0000-0003-3750-7342"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "23", "volume": "132", "journalIssueId": "2758271", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "2446-2455", "abstractText": "Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase \u03b4 and \u03b3 (PI3K-\u03b4,\u03b3) being developed for treatment of hematologic malignancies. PI3K-\u03b4,\u03b3 signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a phase 1 study, duvelisib showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here the results of DUO, a global phase 3 randomized study of duvelisib vs ofatumumab monotherapy for patients with relapsed or refractory (RR) CLL/SLL. Patients were randomized 1:1 to oral duvelisib 25 mg twice daily (n = 160) or ofatumumab IV (n = 159). The study met the primary study end point by significantly improving progression-free survival per independent review committee assessment compared with ofatumumab for all patients (median, 13.3 months vs 9.9 months; hazard ratio [HR] = 0.52; <i>P</i> < .0001), including those with high-risk chromosome 17p13.1 deletions [del(17p)] and/or <i>TP53</i> mutations (HR = 0.40; <i>P</i> = .0002). The overall response rate was significantly higher with duvelisib (74% vs 45%; <i>P</i> < .0001) regardless of del(17p) status. The most common adverse events were diarrhea, neutropenia, pyrexia, nausea, anemia, and cough on the duvelisib arm, and neutropenia and infusion reactions on the ofatumumab arm. The DUO trial data support duvelisib as a potentially effective treatment option for patients with RR CLL/SLL. This trial was registered at www.clinicaltrials.gov as #NCT02004522.", "affiliation": "Sarah Cannon Research Institute, Nashville, TN.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase III", "Comparative Study", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Chromosomes, Human, Pair 17"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Chromosome Deletion"}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Isoquinolines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Purines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antibodies, Monoclonal", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Tumor Suppressor Protein p53", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Lymphocytic, Chronic, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Smith-Magenis Syndrome"}, {"majorTopic_YN": "N", "descriptorName": "Antibodies, Monoclonal, Humanized"}]}, "chemicalList": {"chemical": [{"name": "Purines", "registryNumber": "0"}, {"name": "Isoquinolines", "registryNumber": "0"}, {"name": "Antibodies, Monoclonal", "registryNumber": "0"}, {"name": "Tumor Suppressor Protein p53", "registryNumber": "0"}, {"name": "TP53 protein, human", "registryNumber": "0"}, {"name": "Antibodies, Monoclonal, Humanized", "registryNumber": "0"}, {"name": "ofatumumab", "registryNumber": "M95KG522R0"}, {"name": "duvelisib", "registryNumber": "610V23S0JI"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-05-850461"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6284216"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-05-850461"}]}, "commentCorrectionList": {"commentCorrection": {"id": "30523122", "source": "MED", "reference": "Blood. 2018 Dec 6;132(23):2422-2424", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "48", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-07-16", "dateOfCreation": "2018-10-06", "firstIndexDate": "2018-10-05", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-10-04", "firstPublicationDate": "2018-10-04"}, "abstract": "Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase \u03b4 and \u03b3 (PI3K-\u03b4,\u03b3) being developed for treatment of hematologic malignancies. PI3K-\u03b4,\u03b3 signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a phase 1 study, duvelisib showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here the results of DUO, a global phase 3 randomized study of duvelisib vs ofatumumab monotherapy for patients with relapsed or refractory (RR) CLL/SLL. Patients were randomized 1:1 to oral duvelisib 25 mg twice daily (n = 160) or ofatumumab IV (n = 159). The study met the primary study end point by significantly improving progression-free survival per independent review committee assessment compared with ofatumumab for all patients (median, 13.3 months vs 9.9 months; hazard ratio [HR] = 0.52; <i>P</i> < .0001), including those with high-risk chromosome 17p13.1 deletions [del(17p)] and/or <i>TP53</i> mutations (HR = 0.40; <i>P</i> = .0002). The overall response rate was significantly higher with duvelisib (74% vs 45%; <i>P</i> < .0001) regardless of del(17p) status. The most common adverse events were diarrhea, neutropenia, pyrexia, nausea, anemia, and cough on the duvelisib arm, and neutropenia and infusion reactions on the ofatumumab arm. The DUO trial data support duvelisib as a potentially effective treatment option for patients with RR CLL/SLL. This trial was registered at www.clinicaltrials.gov as #NCT02004522.", "journaltitle": "Blood", "authorinfo": ["Flinn IW", "Hillmen P", "Montillo M", "Nagy Z", "Ill\u00e9s \u00c1", "Etienne G", "Delgado J", "Kuss BJ", "Tam CS", "Gasztonyi Z", "Offner F", "Lunin S", "Bosch F", "Davids MS", "Lamanna N", "Jaeger U", "Ghia P", "Cymbalista F", "Portell CA", "Skarbnik AP", "Cashen AF", "Weaver DT", "Kelly VM", "Turnbull B", "Stilgenbauer S"], "title": "The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL."}